88 related articles for article (PubMed ID: 18836331)
1. Bevacizumab and irinotecan in the treatment of recurrent malignant gliomas.
de Groot JF; Yung WK
Cancer J; 2008; 14(5):279-85. PubMed ID: 18836331
[TBL] [Abstract][Full Text] [Related]
2. Bevacizumab for malignant gliomas.
Iwamoto FM; Fine HA
Arch Neurol; 2010 Mar; 67(3):285-8. PubMed ID: 20212225
[TBL] [Abstract][Full Text] [Related]
3. Experience with irinotecan for the treatment of malignant glioma.
Vredenburgh JJ; Desjardins A; Reardon DA; Friedman HS
Neuro Oncol; 2009 Feb; 11(1):80-91. PubMed ID: 18784279
[TBL] [Abstract][Full Text] [Related]
4. Bevacizumab in high-grade gliomas: a review of its uses, toxicity assessment, and future treatment challenges.
Rahmathulla G; Hovey EJ; Hashemi-Sadraei N; Ahluwalia MS
Onco Targets Ther; 2013; 6():371-89. PubMed ID: 23620671
[TBL] [Abstract][Full Text] [Related]
5. Peritumoral Edema in Gliomas: A Review of Mechanisms and Management.
Ohmura K; Tomita H; Hara A
Biomedicines; 2023 Oct; 11(10):. PubMed ID: 37893105
[TBL] [Abstract][Full Text] [Related]
6. New therapies for recurrent glioblastomas.
Wen PY
F1000 Med Rep; 2009 Dec; 1():. PubMed ID: 20948683
[TBL] [Abstract][Full Text] [Related]
7. Anti-Cancer Effect of Neural Stem Cells Transfected with Carboxylesterase and sTRAIL Genes in Animals with Brain Lesions of Lung Cancer.
Kim JH; Ahn JS; Lee DS; Hong SH; Lee HJ
Pharmaceuticals (Basel); 2023 Aug; 16(8):. PubMed ID: 37631070
[TBL] [Abstract][Full Text] [Related]
8. Angiogenesis in Breast Cancer Progression, Diagnosis, and Treatment.
Madu CO; Wang S; Madu CO; Lu Y
J Cancer; 2020; 11(15):4474-4494. PubMed ID: 32489466
[TBL] [Abstract][Full Text] [Related]
9. Super selective intra-arterial cerebral infusion of modern chemotherapeutics after blood-brain barrier disruption: where are we now, and where we are going.
D'Amico RS; Khatri D; Reichman N; Patel NV; Wong T; Fralin SR; Li M; Ellis JA; Ortiz R; Langer DJ; Boockvar JA
J Neurooncol; 2020 Apr; 147(2):261-278. PubMed ID: 32076934
[TBL] [Abstract][Full Text] [Related]
10. Volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastoma.
Ellingson BM; Aftab DT; Schwab GM; Hessel C; Harris RJ; Woodworth DC; Leu K; Chakhoyan A; Raymond C; Drappatz J; de Groot J; Prados MD; Reardon DA; Schiff D; Chamberlain M; Mikkelsen T; Desjardins A; Holland J; Ping J; Weitzman R; Wen PY; Cloughesy TF
Neuro Oncol; 2018 Sep; 20(10):1411-1418. PubMed ID: 29660005
[TBL] [Abstract][Full Text] [Related]
11. Modified Criteria for Radiographic Response Assessment in Glioblastoma Clinical Trials.
Ellingson BM; Wen PY; Cloughesy TF
Neurotherapeutics; 2017 Apr; 14(2):307-320. PubMed ID: 28108885
[TBL] [Abstract][Full Text] [Related]
12. Leakage decrease detected by dynamic susceptibility-weighted contrast-enhanced perfusion MRI predicts survival in recurrent glioblastoma treated with bevacizumab.
Hilario A; Sepulveda JM; Hernandez-Lain A; Salvador E; Koren L; Manneh R; Ruano Y; Perez-Nuñez A; Lagares A; Ramos A
Clin Transl Oncol; 2017 Jan; 19(1):51-57. PubMed ID: 27026567
[TBL] [Abstract][Full Text] [Related]
13. Antiangiogenic mechanisms and factors in breast cancer treatment.
Castañeda-Gill JM; Vishwanatha JK
J Carcinog; 2016; 15():1. PubMed ID: 27013929
[TBL] [Abstract][Full Text] [Related]
14. Bevacizumab and radiotherapy for the treatment of glioblastoma: brothers in arms or unholy alliance?
Niyazi M; Harter PN; Hattingen E; Rottler M; von Baumgarten L; Proescholdt M; Belka C; Lauber K; Mittelbronn M
Oncotarget; 2016 Jan; 7(3):2313-28. PubMed ID: 26575171
[TBL] [Abstract][Full Text] [Related]
15. Pros and cons of current brain tumor imaging.
Ellingson BM; Wen PY; van den Bent MJ; Cloughesy TF
Neuro Oncol; 2014 Oct; 16 Suppl 7(Suppl 7):vii2-11. PubMed ID: 25313235
[TBL] [Abstract][Full Text] [Related]
16. Validation of the prognostic Heidelberg re-irradiation score in an independent mono-institutional patient cohort.
Niyazi M; Flieger M; Ganswindt U; Combs SE; Belka C
Radiat Oncol; 2014 Jun; 9():128. PubMed ID: 24893775
[TBL] [Abstract][Full Text] [Related]
17. Re-irradiation and bevacizumab in recurrent high-grade glioma: an effective treatment option.
Flieger M; Ganswindt U; Schwarz SB; Kreth FW; Tonn JC; la Fougère C; Ertl L; Linn J; Herrlinger U; Belka C; Niyazi M
J Neurooncol; 2014 Apr; 117(2):337-45. PubMed ID: 24504501
[TBL] [Abstract][Full Text] [Related]
18. Early response evaluation for recurrent high grade gliomas treated with bevacizumab: a volumetric analysis using diffusion-weighted imaging.
Hwang EJ; Cha Y; Lee AL; Yun TJ; Kim TM; Park CK; Kim JH; Sohn CH; Park SH; Kim IH; Heo DS; Lee SH; Choi SH
J Neurooncol; 2013 May; 112(3):427-35. PubMed ID: 23417358
[TBL] [Abstract][Full Text] [Related]
19. Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype.
Piao Y; Liang J; Holmes L; Zurita AJ; Henry V; Heymach JV; de Groot JF
Neuro Oncol; 2012 Nov; 14(11):1379-92. PubMed ID: 22965162
[TBL] [Abstract][Full Text] [Related]
20. Passive immunotherapeutic strategies for the treatment of malignant gliomas.
Nagasawa DT; Fong C; Yew A; Spasic M; Garcia HM; Kruse CA; Yang I
Neurosurg Clin N Am; 2012 Jul; 23(3):481-95. PubMed ID: 22748660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
